rs63751049
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The ENST00000231790.8(MLH1):c.977T>A(p.Val326Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V326A) has been classified as Benign.
Frequency
Consequence
ENST00000231790.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.977T>A | p.Val326Glu | missense_variant | 11/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.977T>A | p.Val326Glu | missense_variant | 11/19 | 1 | NM_000249.4 | ENSP00000231790 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 22, 2019 | The p.V326E variant (also known as c.977T>A), located in coding exon 11 of the MLH1 gene, results from a T to A substitution at nucleotide position 977. The valine at codon 326 is replaced by glutamic acid, an amino acid with dissimilar properties. This alteration has been detected in a proband diagnosed with early-onset colon cancer whose family history met Amsterdam I criteria for Lynch syndrome, but results from microsatellite instability (MSI) and immunohistochemistry (IHC) testing were unavailable (Ambry internal data). In another family, this variant was detected in two first-degree relatives diagnosed with Lynch syndrome-associated cancers and the colon cancer of the proband was MSI-H with loss of both MLH1/PMS2 expression by IHC (Ambry internal data). This alteration was also identified as somatic along with a somatic MLH1 pathogenic mutation in a MSI-H colon tumor that displayed loss of both MLH1/PMS2 expression by IHC and no MLH1 promoter hypermethylation was detected (Ambry internal data). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. In addition, this alteration is predicted to be deleterious by MAPP-MMR in silico analyses (Chao EC et al. Hum. Mutat. 2008 Jun;29:852-60). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Sep 24, 2020 | This missense variant replaces valine with glutamic acid at codon 326 of the MLH1 protein. Computational prediction tools and conservation analyses suggest that this variant may have deleterious impact on the protein function. Computational splicing tools suggest that this variant may not impact RNA splicing. To our knowledge, functional assays have not been performed for this variant. This variant has been detected in at least three individuals affected with colorectal cancer, in which one proband's health history has met the Amsterdam I criteria (communication with an external laboratory), and in two individuals affected with colorectal cancer before age 50 and the colon tumor sample from one proband confirmed to exhibit microsatellite instability with loss of MLH1 protein by immunohistochemistry (internal data). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on available evidence, this variant is classified as Likely Pathogenic. - |
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 07, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MLH1 protein function. ClinVar contains an entry for this variant (Variation ID: 231925). This missense change has been observed in individual(s) with clinical features of MLH1-related conditions (PMID: 21520333). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces valine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 326 of the MLH1 protein (p.Val326Glu). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at